- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00974896
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
October 26, 2016 updated by: NantCell, Inc.
A Phase 1b Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects with advanced solid tumors.
Up to 126 subjects may be enrolled.
Sorafenib and erlotinib combo cohorts are enrolling.
All other combo cohorts are closed to enrollment.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved informed consent form
- Men and women ≥ 18 years old with a pathologically or cytologically documented, advanced solid tumor that is refractory to at least one line of therapy or for whom no standard therapy is available and for which no curative therapy is available, or the subject refuses standard non-curative therapy
- Measurable disease or evaluable disease per World Health Organization (WHO) guidelines
- Eastern Cooperative Oncology Group performance status ≤ 2
- Life expectancy of 3 months as documented by the investigator
- Adequate hematologic, renal and hepatic function
Exclusion Criteria:
- Any co-morbid medical condition that would increase the risk of toxicity in the opinion of Investigator or Sponsor
- Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia
- Subjects with primary or metastatic central nervous system (CNS) tumors are not allowed to enroll in the sorafenib cohorts. These subjects are allowed to enroll in the remaining cohorts, only if their CNS tumors have been controlled by prior surgery or radiation, and they have been neurologically stable
- History of lymphoma, leukemia, or high-dose chemotherapy with hematopoietic stem cell rescue
- Uncontrolled hypertension [diastolic >100 mmHg or systolic >150 mmHg]; Subjects enrolling in the sorafenib groups must not have diastolic > 85 mmHg nor systolic > 145 mmHg
- Clinically significant ECG changes which obscure the ability to assess the PR, QT, QRS intervals
- Presence of ascites or pleural effusion requiring chronic medical intervention
- Diagnosis of arterial or venous thrombosis within 6 months before enrollment; history of bleeding diathesis
- History of clinically significant hypoglycemia or hyperglycemia in the opinion of the investigator
- Myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (New York Heart Association >class II), unstable angina, or unstable cardiac arrhythmia requiring medication
- Active peptic ulcer disease
- History of chronic hepatitis
- Subject known to have tested positive for HIV
- Known sensitivity to mammalian derived products
- Hematological function, as follows:
- Absolute neutrophil count (ANC) ≤ 1.5 x 109/L for B, P, S and E cohorts
- Absolute neutrophil count (ANC) ≤ 3 x 109/L for G cohorts
- Platelet count ≤ 100 x 109/L
- Hemoglobin ≤ 9 g/dL
- Renal function, as follows:
- Calculated creatinine clearance < 50 ml/min using the modified Cockroft-Gault equation
- Urinary protein quantitative value of > 30 mg or >1+ on dipstick, unless quantitative protein is < 500 mg in a 24 hour urine sample
- Hepatic function, as follows:
- Aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN) (if liver metastases are present, ≥ 5 x ULN)
- Alanine aminotransferase (ALT) > 2.5 x ULN (if liver metastases are present, ≥ 5 x ULN)
- Alkaline phosphatase > 2.0 x ULN (if bone or liver metastases are present, ≥ 5 x ULN)
- Bilirubin > 2.0 x ULN
- Prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5 x ULN
- Treatment with anti-cancer therapy (6 weeks for nitrosoureas and mitomycin C chemotherapies), antibody therapy, retinoid therapy, or hormonal therapy within 4 weeks before study day 1. Prior and concurrent use of hormone replacement therapy or the use of gonadotropin-releasing hormone (GnRH) modulators for prostate cancer are permitted
- Therapeutic or palliative radiation therapy within 4 weeks before enrollment (subjects must have resolution of any significant adverse effects from radiation therapy received prior to 2 weeks before enrollment)
- Concurrent or prior (within 1 week of study Day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) for prophylaxis against central venous catheter thrombosis
- Prior participation in clinical drug trials within 4 weeks before enrollment
- For subjects receiving erlotinib, the use of ketoconazole, clarithromycin, voriconazole, troleandomycin, telithromycin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. John's Wort is prohibited
- For subjects receiving sorafenib, use of St. John's Wort, rifampin, phenytoin, carbamazepine, dexamethasone, and phenobarbital (CYP3A inducers) is prohibited
- Type 1 or 2 diabetics are excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AMG 479 + Sorafenib cohorts
The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib.
AMG 479 will be given bi-weekly; sorafenib will be given daily.
|
AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling.
AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
|
Experimental: AMG 479 + Erlotinib cohorts
The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib.
AMG 479 will be given bi-weekly; erlotinib will be given daily.
|
AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling.
AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib or gemcitabine in subjects with advanced solid tumors
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate pharmacokinetic (PK) profiles of biologics or chemotherapy when used in combination with AMG 479
Time Frame: 3 years
|
3 years
|
To evaluate tumor response as assessed by World Health Organization (WHO) criteria
Time Frame: 3 years
|
3 years
|
To evaluate tumor response as measured by volumetric computed tomography (CT)
Time Frame: 3 years
|
3 years
|
To evaluate anti-AMG 479 antibody response following AMG 479 administration
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
September 10, 2009
First Submitted That Met QC Criteria
September 10, 2009
First Posted (Estimate)
September 11, 2009
Study Record Updates
Last Update Posted (Estimate)
October 27, 2016
Last Update Submitted That Met QC Criteria
October 26, 2016
Last Verified
October 1, 2016
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on AMG 479
-
Jonsson Comprehensive Cancer CenterNantCell, Inc.No longer available
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Brigham and Women's Hospital; Amgen; H. Lee Moffitt...CompletedNeuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine TumorUnited States
-
PfizerTerminatedMetastatic Pancreatic Adenocarcinoma | BRAF Mutated MelanomaUnited States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
-
NantCell, Inc.CompletedSarcoma | Ewing's Sarcoma | Primitive Neuroectodermal Tumors (PNETs) | Askin's Tumors | Desmoplastic Small Round Cell Tumors | Estraosseous Ewing's Tumor | Ewing's Family Tumor
-
Novartis PharmaceuticalsNantCell, Inc.TerminatedPIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid TumorsSpain, Belgium, United States, Canada
-
Translational Research in OncologyTerminatedOvarian NeoplasmsUnited States, France, Germany, Israel, Ireland, Spain, Canada, United Kingdom
-
Translational Research in OncologyCompletedStudy of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian CancerOvarian NeoplasmsUnited States, France, Ireland, Germany, Israel, Canada, Spain
-
NantCell, Inc.TerminatedSarcoma | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Metastatic Cancer | Solid Tumors | Locally Advanced
-
M.D. Anderson Cancer CenterAmgenWithdrawn
-
AmgenCompletedMetastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal Cancer